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Highlights 
 We  have examined the action of 1,25D3 and vitamin D analogues (VDAs) on 
malignant and healthy B cells. 
 1,25D3 and VDAs displayed moderate cytotoxic and pro-apoptotic actions upon 
DLBCL cells.  
 1,25D3 and VDAs displayed concentration and time-dependent anti-proliferative 
actions upon stimulated B-cells from healthy donors.  
 VDAs may offer therapeutic potential for the treatment of DLBCL or conditions 
benefitted by B-cell depletion. 
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Abstract  
Calcitriol (1,25-dihydroxyvitamin D3,  1,25D3) and vitamin D side-chain modified 
analogs (VDAs) have gained considerable attention as potential drugs in the treatment of 
acute myeloid leukemia (AML), yet studies of the impact of 1,25D3 and VDAs upon 
other haematological malignancies are more limited. To address this gap in knowledge, 
we have examined the action of 1,25D3 and VDAs on a human cell line (DOHH2, K422) 
typifying diffuse large B-cell lymphoma (DLBCL) and also peripheral blood B-cells 
isolated from healthy donors.  
1,25D3 and certain VDAs displayed moderate cytotoxic and pro-apoptotic actions upon 
DLBCL cells. 1,25D3 and VDAs (100 nM) caused the death of approximately 40% 
DOHH2 cells after 24 hours stimulation, similar to their impact on HL-60 cells (acute 
myeloid leukaemia cell line). In addition, 1,25D3 and VDAs displayed concentration and 
time-dependent anti-proliferative actions upon stimulated B-cells from healthy donors. 
The VDAs inhibited proliferation by approximately 30%. Hence VDAs may offer 
therapeutic potential for the treatment of DLBCL or conditions benefitted by B-cell 
depletion. 
 
Keywords: vitamin D analogues; B-cells; Diffuse Large B-cell lymphoma; proliferation; drug 
synergy 
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1. Introduction 
Calcitriol (1,25-dihydroxyvitamin D3; 1,25D3) impacts physiological processes in the 
human body, with perhaps the most notable being the regulation of Ca2+ and phosphate 
(Pi) transport and bone mineralization [1]. Other actions include control of the growth, 
differentiation and functional activity of numerous cell types including those of the skin, 
immune system and pancreas [2]. 
Numerous studies demonstrate that the active form of vitamin D promotes the 
differentiation of HL-60 cells (a cell line that typifies acute myeloid leukaemia AML) to a 
phenotype resembling differentiated monocytes in bone marrow [3], such that majority of 
cells are now CD14+ cells [4]. Similar results have been obtained for cell lines of 
biologically related origin, e.g. THP-1 and U-937 cells [5, 6]. In addition to the pro-
differentiative effects of 1,25D3, considerable attention has been paid to its cytotoxic and 
anti-proliferative actions. This has been studied in various mouse models, human cultured 
breast and colon cancers and also in HL-60 cells, which growth arrest in the G1 phase of 
cell cycle [7-9]. It should be noted however that the antitumor activity of 1,25D3 is 
evident at supra-physiological concentrations, which also promote hypercalcemia and 
hypercalciuria [10], which are likely to limit therapeutic potential. This has motivated the 
search for vitamin D analogues (VDAs) with less propensity to increase Ca2+ levels. 
Some identified compounds retain interaction with the VDR and the anti-
proliferative/pro-differentiative capacity but display more limited effect on calcium levels 
in comparison to 1,25D3 [11].  
Lymphoma is a cancer of lymphocytes presenting as either Hodgkin’s (HL) or non-
Hodgkin’s lymphoma (NHL); over 90% of all NHL are of B-cell origin. According to the 
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Cancer Research UK statistics over 12,000 people are diagnosed with NHL every year in 
the UK which makes it the 6th most common cancer in this country and the 11th most 
common cause of cancer death worldwide. As many as 40% of people diagnosed with 
this disease are predicted to survive less than 10 years.   
It is estimated that 50% of NHL cases in the UK and 25-35% worldwide can be 
categorised as diffuse large B-cell lymphoma (DLBCL) [12]. DLBCL is an aggressive 
malignancy of B lymphocytes of germinal centre origin and is characterised by the 
presence of rapidly proliferating large cells with basophilic cytoplasm and vesicular 
nuclei [13]. Current treatments for DLBCL include the anti-CD20 monoclonal antibody, 
rituximab, and cycles of a combination of cyclophosphamide, doxorubicin, vincristine, 
prednisone (CHOP). Unfortunately, rituximab-CHOP treatment (R-CHOP) can be 
associated with severe toxicity and only displays failure-free survival of 65% after 3 
years [14]. 
There is little data concerning the therapeutic potential of vitamin D analogues for the 
treatment of NHL. To address further therapeutic potential from 1,25D3 and VDAs, we 
investigate in the present study the impact of 1,25D3 and novel VDAs upon DOHH2 and 
K422, cell lines representative of DLBCL, as well as B-cells from healthy donors. 
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2. Experimental 
2.1 Vitamin D analogues 
1,25D3 and all analogues (PRI-1890, PRI-1906, PRI-2191, PRI-2205; Fig. 1) were 
synthesized in the Pharmaceutical Research Institute (Warsaw, Poland). The 
compounds were dissolved in absolute ethanol, the concentration adjusted to 100 µM 
and the aliquots stored at -20ºC prior to experiments. 
 
2.2 Cell culture 
HL-60 and DOHH-2 cells were cultured in RPMI-1640 medium (Sigma Aldrich, UK) 
supplemented with 1 % L-glutamine (Life Technologies), 1 % penicillin/streptomycin 
(Sigma Aldrich, 10000 units penicillin and 10 mg streptomycin per ml) and 10 % 
heat-inactivated fetal bovine serum (later referred as: FBS HI, Sigma Aldrich). Cells 
were subcultured at a density of 1 – 1.5 x 106 cells/ml. 
 
2.3 Isolation of human peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells were isolated from whole blood from healthy 
donors or from Leukocyte Reduced System (LRS) cones using Ficoll–Paque (GE 
Healthcare). 20 ml of blood was layered on 25 ml of Ficoll-Paque and centrifuged at 
900 x g for 30 minutes. The PBMC layer was mixed with RPMI in a new tube and 
centrifuged an additional three times, at 400 x g for 10 minutes, 8 minutes and 5 
minutes respectively.  
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2.4 Preparation of cell nuclear fractions 
Cells were washed twice with PBS and resuspended in an ice-cold lysis buffer (10 
mM Tris, pH 7.4, 1 mM EGTA, 200 mM sucrose) with protease inhibitors (Sigma 
Aldrich). The lysates were centrifuged for 5 min at 18000 x g at 4˚C and disrupted by 
sonication on ice 3 x 3 seconds. The protein concentration in the lysates was 
measured using a Bradford protein assay. 
 
2.5 SDS-PAGE and Western blot 
The lysates were treated with Radioimmunoprecipitation assay buffer (RIPA)  (20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 
1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 0.5 mM PMSF) and gel sample 
buffer containing 12% sodium dodecyl sulfate and 10% β-mercapto-ethanol. Samples 
were placed in boiling water for 10 minutes and cooled down on ice before loading 
onto a gel. Typically 15 µg of proteins were loaded onto 12% Tris-Glycine gel and 
run at 35 mA for about 2 hours  Proteins were then transferred to PVDF membranes 
which were then blocked in 10% non-fat milk for 2 hours at room temperature. 
Membranes were then incubated in primary mouse anti-human VDR antibody 
(SantaCruz, clone D6, used at 1:200 dilution) in 5% non-fat milk overnight at 4ºC. 
Membranes were washed and incubated subsequently in secondary antibody (Cell 
Signalling, horse anti-mouse IgG HRP linked, used at 1:3,000 dilution)  in 5% non-fat 
milk at room temperature for 2 hours. The protein bands were visualized with 
chemiluminescence. 
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2.6 Determination of cell apoptosis and necrosis using PhiPhiLux and propidium iodide  
Cells were stimulated for the indicated periods of time and following the incubation 
were washed with PBS by centrifugation at 400 x g for 5 minutes. The supernatant 
was discarded and cells were resuspended in 60 µl of PhiPhiLux solution and 
incubated for 30 minutes at 37°C. PBS was added to each well and the plate 
centrifuged at 400 x g for 5 minutes. Cells were resuspended using flow cytometry 
buffer (supplied in the PhiPhiLux kit) and 2 minutes before running the samples on 
the cytometer, propidium iodide was added to a final concentration of 5 µg/ml.  
 
2.7 Determination of cell proliferation using eFluor450 proliferation dye 
PBMCs were resuspended in PBS to a concentration of 20 x 106 cells/ml and labelled 
with  eFluor450 (20 µM). The cell suspension was incubated at 37°C (protected from 
light) for 20 minutes. To stop the reaction 10 ml cold complete media was added to 
the cells and left for 5 minutes. The cells were centrifuged 3 times (400 x g for 5 
minutes) in 30 ml of ice-cold complete medium. After the final wash the cells were 
plated in 96-well plate along with test compounds or vehicle. Cells were incubated for 
3, 5 and 7  days in the presence of Protein A from Staphylococcus aureus  (SAC,  
1:10,0000) and  Interleukin-2 (IL-2, 20 units/ml). The cells were washed twice with 
PBS and stained with mouse anti-human CD19 antibody PE conjugated (BD) for 20 
minutes at 4ºC. The cells were again washed and resuspended in 1% FBS in PBS 
buffer, before assay by flow cytometry (with the addition of a known number of 
counting beads). 
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2.8 Statistical analysis 
Where applicable multiple comparisons statistical tests were performed  in GraphPad 
Prism 6 software using one-way ANOVA which was followed by the Bonferroni 
post-test.  
 
3. Results and discussion 
There are already a few reports describing the impact of vitamin D on B-cells. It is 
known that normal B-cells express VDR at very low levels though the protein is up-
regulated following the stimulation of the cells [15].  Malignant B-cells express VDR 
and both Hodgkin’s and Non-Hodgkin’s lymphoma cells have relatively high levels 
of this protein [16]. It has been shown that 1,25D3 inhibits proliferation of anti-CD40, 
anti-IgM, and IL-21 stimulated B-cells [17]. 1,25D3 has also been shown to up-
regulate the production of IL-10 in stimulated B-cells [18]. Of relevance, it has been 
shown recently that vitamin D deficiency has been associated with significantly 
poorer outcome in DLBCL patients treated with rituximab [19].  
 
3.1 VDR is expressed by DOHH2 cells and its nuclear translocation is induced after 
application of VDAs 
Expression of VDR in nuclear fractions of DOHH2 cells was assessed after 
stimulation with 1,25D3 or various VDAs (all at 10 nM) for 48 hours. HL-60 cells 
were included as a positive control (Fig. 2). 1,25D3 and the VDAs all increased the 
expression of VDR protein. Similarly VDR up-regulation in the nuclear fraction by 
1,25D3 was evident in HL-60 cells (Fig. 2). 
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It has to be noted that there is a discrepancy in the literature between binding 
affinities of the VDAs to VDR and their biological profile. Other analogues of 
vitamin D have been reported to bind to the receptor with much lower affinities than 
the active form of vitamin D, yet some of them had more pronounced biological 
activities (e.g. anti-proliferative properties, lower calcemic effects) than the parent 
compound [20, 21]. One of the possible explanations for this phenomenon is that 
upon binding to the VDR downstream signaling actions differ, which manifests 
differences [22] Alternatively the discrepancy between the binding affinities and the 
biological activities of the VDAs may be explained by their differential susceptibility 
to metabolism by CYP24A1. Indeed it may also be relevant that the expression of this 
enzyme is differentially induced in cell lines by structurally distinct VDAs [23]. 
 
3.2 VDAs are cytotoxic to DOHH2 and HL-60 cells 
The impact of 1,25D3 and VDAs upon the viability of the DOHH2 and HL-60 cells 
was assessed at different time points  (24, 48 and 72 hours). 1,25D3 and VDAs (100 
nM) were toxic to cells with cell death primarily associated with necrosis rather than 
apoptosis. DOHH2 cells were most prone to the VDAs following 24 hours treatment 
however no clear differences were evident between different analogues (Fig. 3 A). At 
the two later time points we assume that the compounds have lost their activity 
(perhaps due to metabolism) and that the cells affected at the early stages of culture 
have died and hence do not for part of the analyses at 48 and 72h.  On the contrary, 
the viability of HL-60 cells decreased with time and was the lowest after 72 hours 
(Fig. 3 B). In K422 cells cytotoxicity of vitamin D and some analogues – albeit less 
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pronounced that in DOHH-2 cells - has been retained as was the impact of 
staurosporine, suggesting the greater resistance of the cell line (Fig. 3 C) 
 
3.3 VDAs inhibit the proliferation of stimulated CD19+ B-cells 
Next, we examined the effects of 1,25D3 and VDAs on anti-CD19 labelled B-cells 
from PBMCs obtained from healthy donors. B-cells within the PBMC population 
were induced to proliferate in response to SAC/IL-2 [24]. The cells were kept in 
culture for 7 days to assess the impact of VDAs (1, 10 and 100 nM; Fig. 4) 
1,25D3 and VDAs decreased the number of proliferated CD19+ after 7 days in a 
concentration-dependent manner indicating that VDAs inhibit the proliferation on 
SAC/IL-2 stimulated normal B-cells, which potentially may serve as beneficial in 
diseases diagnosed with over proliferating B-cells, such as systemic lupus 
erythematous (SLE) or rheumatoid arthritis (RA) [25, 26]. 
 
3.3 VDAs and clomipramine cooperate in their anti-proliferative effects 
Many studies have demonstrated that 1,25D3 and some analogues can enhance the 
anti-proliferative efficacy of various chemotherapeutics in different cancer cells [9, 
27]. In addition, with the realisation that a single drug modality – a single ‘magic 
bullet’ – is unlikely to offer complete molecular remission, we have also investigated 
potential synergies of VDAs with other drugs. In the present study we report the 
VDA combination with the anti-depressant drug clomipramine. Clomipramine has 
been shown to be cytotoxic and pro-apoptotic against glioma cells [28] and anti-
proliferative against malignant, and to a lesser extent, normal B-cells [29, 30]. In 
previous studies [30, 31] 5 - 10 µM clomipramine was used to demonstrate activity in 
proliferation assays. The goal of the polytherapy is to obtain similar or higher 
potential therapeutic outcome with lower adverse effects by combining 2 or more 
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active compounds in lower concentrations. Therefore clomipramine was used here at 
1 µM. In the present study we applied clomipramine with a range of 1,25D3 and 
VDAs concentrations (1, 10 and 100 nM) to SAC/IL-2 stimulated PBMCs for 7 days 
and demonstrated an increase in the action of the drug combination in comparison 
with either drug alone (Fig. 5), however these increases did not reach statistical 
significance. 
 
4. Conclusions 
In summary, this study demonstrates that relatively high concentrations of 1,25D3 and 
vitamin D analogues are cytotoxic to DOHH2 cells (with less pronounced effect in K422 
cells) with the extent of killing similar to that observed against HL-60 cells. We have also 
shown that DOHH2 cells express VDR and that ligand engagement increases expression. 
From this, we conclude that DOHH2 is a good model to study the effects of 1,25D3 and 
derived compounds in DLBCL. VDAs also inhibited the proliferation of SAC/IL-2 
stimulated normal B-cells in a concentration-dependent manner. This effect was 
enhanced when the analogues were used in combination with the tricyclic anti-depressant 
clomipramine. Together, this work identifies the potential of using VDAs in a variety of 
malignant and non-malignant B-cell diseases. 
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Figure 1. Structures of calcitriol (1,25D3) and vitamin D2 analogues that were used in the 
present study. 
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Figure 2. Expression of VDR immunoreactivity in nuclear fractions of HL-60 (lanes 1 and 2) and 
DOHH2 (lanes 4-9). Cells were treated for 48 hours with 10 nM of each compound or vehicle 
control. 15 µg of protein were loaded for each well. Histone H3 immunoreactivity was used as a 
loading control. A representative example of two independent experiments with similar results is 
shown. 
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Figure 3. Impact of 1,25D3 and some VDAs upon viability of (A) DOHH2, (B) HL-60 cells and 
(C) K422 cells following different treatment for 3 different time periods assayed by PhiPhiLux 
assay. PRI-1906 markedly increased the number of necrotic HL-60 cells after 72 hours. 
Representative flow cytometry plots (D) for DOHH2 cells (from left to right: control, 1,25D3, 
PRI-1890 and PRI-1906 at 100 nM). Data represent mean ± SD, n=3. *** (P < 0.01), ** 
(P<0.05), * (P<0.1) compared with Control. 
 22 
 
Figure 4.   VDAs have anti-proliferative effects on SAC/IL-2 stimulated CD19+ B- cell (7 days). 
Data represent mean ± SD from 3 independent experiments.*** (P < 0.01), ** (P<0.05), * 
(P<0.1) compared with SAC/IL-2 stimulated cells.  
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Figure 5.   Additive anti-proliferative effect of the combination of 1,25D3 and VDAs (indicated 
concentrations)  with clomipramine (Clo; 1 µM) on SAC/IL-2 stimulated CD19+ B-cells. Cells 
were stimulated for 7 days and labelled with CD19 antibody. Data represent mean ± SD from 3 
independent experiments.*** (P < 0.01), ** (P<0.05), * (P<0.1) compared with SAC/IL-2 
stimulated cells. No statistically significant differences were found when the combinations of 
VDAs wth Clo  were compared to VDAs used alone. 
